Any current/future new fundraising through debt or equity?

Fabtech Technologies Limited has raised funds through an IPO recently, with funds parked in Fixed Deposits earning interest (other income). There is no explicit mention of imminent new fundraising through equity or debt in the transcript. The company is focusing on executing existing orders and growing organically, including through acquisitions. They have a "war chest for acquisitions," implying availability of funds for strategic purchases. No specific new equity or debt raising plans were stated for the near future during the call.

Any current/future capex/capital investment/strategic investment?

Fabtech Technologies Limited has raised funds through an IPO to invest in strategic areas. The company is planning acquisitions in Europe, UAE, and Saudi Arabia to strengthen local presence and conversion rates. Investments are being made to own processes, IPs, and increase ticket sizes for bigger turnkey projects. Fabtech is focusing on infrastructure projects including green energy options like solar (tied up with KP Greens). They are preparing to expand beyond life sciences into sectors like data centers and semiconductors when the time is right. The company is investing in building a stron

Future growth expectations in sales/revenue/volumes?

Fabtech Technologies targets a year-on-year growth of **30%** starting FY27 (Page 16). Execution of a **900 crore order book** is expected mostly in the next financial year, with about **30-40% spilling into Q1/Q2 FY28** (Page 16). Average ticket size has increased to between **7 to 10 million dollars**, up from earlier 1.5 to 3 million dollars, boosting volumes and margins (Page 9, 22). Increased presence and leveraging of markets in **UAE, Saudi Arabia, and eco-African regions** to drive volume growth and margin improvement (Page 22). The company aims to capitalize on the growing medicinal i

Future growth expectations in earnings/operating earnings/profits/EPS?

Profit After Tax (PAT) margins are expected to remain between 9% to 11%. There is flexibility to improve margins by rationalizing marketing and business development expenses, currently around ₹8.5 - 9 crores annually. Operating profit margins are anticipated to benefit from increased ticket sizes, with orders moving from $1.5–3 million to $7–10 million. Higher ticket sizes and expanded geographic leverage (UAE, Saudi, Eco-African region) are expected to enhance volumes and operating margins. The company's focus on life sciences infrastructure and growing market presence in emerging geographies

Current/ Expected Orderbook/ Pending Orders?

As of January end, the order book stands at approximately INR 926 crore. The order book is almost entirely export-focused, targeting international markets, primarily in emerging economies. The company has a healthy pipeline of hot leads valued around USD 455 million. Execution timeline for the current order book is expected to span 9 to 18 months, with efforts underway to expedite deliveries. Major portion of the order book is expected to be executed in the next financial year, with roughly 30-40% spilling over into Q1 or Q2 of FY28. The average ticket size of orders is increasing, currently a

IN US

Sale is live|00:00:00left today

Fabtech Technologies LtdQ4 FY27Healthcare Services

Fabtech Technologies Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹157P/E: 20.3Market Cap: ₹750 CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Fabtech Technologies targets a year-on-year growth of **30%** starting FY27 (Page 16).
→Execution of a **900 crore order book** is expected mostly in the next financial year, with about **30-40% spilling into Q1/Q2 FY28** (Page 16).
→Average ticket size has increased to between **7 to 10 million dollars**, up from earlier 1.5 to 3 million dollars, boosting volumes and margins (Page 9, 22).
→Increased presence and leveraging of markets in **UAE, Saudi Arabia, and eco-African regions** to drive volume growth and margin improvement (Page 22).
→The company aims to capitalize on the growing medicinal independence movement in emerging markets, expanding its life sciences infrastructure footprint (Page 14).
→Growth is supported by in-house design and manufacturing capabilities, and potential acquisitions further strengthening market position (Page 13).
→Quarterly fluctuations expected, but annual growth guidance remains intact (Page 13).

Margin guidance

Category 3

→Profit After Tax (PAT) margins are expected to remain between 9% to 11%.
→There is flexibility to improve margins by rationalizing marketing and business development expenses, currently around ₹8.5 - 9 crores annually.
→Operating profit margins are anticipated to benefit from increased ticket sizes, with orders moving from $1.5–3 million to $7–10 million.
→Higher ticket sizes and expanded geographic leverage (UAE, Saudi, Eco-African region) are expected to enhance volumes and operating margins.
→The company's focus on life sciences infrastructure and growing market presence in emerging geographies indicates sustained revenue growth.
→Strong order book (₹900 crore) with execution expected to pick up by Q1 FY28 supports growth visibility.
→Operating cash flow may remain negative during high growth phases due to working capital cycles but is expected to improve post-growth stabilization.
→EPS growth likely aligns with PAT growth guided between ₹39–41 crores for FY26.

3 more insights locked — sign up free to unlock

Fundraise plans

→Fabtech Technologies Limited has raised funds through an IPO recently, with funds parked in Fixed Deposits earning interest (other income).
→There is no explicit mention of imminent new fundraising through equity or debt in the transcript.
→The company is focusing on executing existing orders and growing organically, including through acquisitions.
→They have a "war chest for acquisitions," implying availability of funds for strategic purchases.
→No specific new equity or debt raising plans were stated for the near future during the call.

Order book

Yes

→As of January end, the order book stands at approximately INR 926 crore.
→The order book is almost entirely export-focused, targeting international markets, primarily in emerging economies.
→The company has a healthy pipeline of hot leads valued around USD 455 million.
→Execution timeline for the current order book is expected to span 9 to 18 months, with efforts underway to expedite deliveries.
→Major portion of the order book is expected to be executed in the next financial year, with roughly 30-40% spilling over into Q1 or Q2 of FY28.
→The average ticket size of orders is increasing, currently around USD 7 million, with hot leads ranging between USD 7 to 10 million.
→Order inflow has remained strong without cancellations or pricing pressures, signaling sustained demand.

Capex plans

Yes

→Fabtech Technologies Limited has raised funds through an IPO to invest in strategic areas.
→The company is planning acquisitions in Europe, UAE, and Saudi Arabia to strengthen local presence and conversion rates.
→Investments are being made to own processes, IPs, and increase ticket sizes for bigger turnkey projects.
→Fabtech is focusing on infrastructure projects including green energy options like solar (tied up with KP Greens).
→They are preparing to expand beyond life sciences into sectors like data centers and semiconductors when the time is right.
→The company is investing in building a strong design platform across process, air, and water domains with homegrown companies.
→Capital is being allocated towards marketing and business development (8.5 to 9 crores annually) with some flexibility.
→Preparing for expedited civil construction by clients to improve conversion and execution.
→Exiting TSA Process Equipments Pvt Ltd (water solutions) in the current financial year as part of capital allocation strategy.

How does Fabtech Technologies Ltd rank vs peers in Healthcare Services?

Pro feature

1Fabtech Technologies Ltd

Rev 2Mar 3

See full Healthcare Services sector rankings

Want more stocks like Fabtech Technologies Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio